Literature DB >> 25419441

Molecular Heterogeneity of Triple Negative Breast Cancer.

Vandana G Abramson1, Ingrid A Mayer1.   

Abstract

Triple-negative breast cancers (TNBCs) are known to be an aggressive group of breast cancers with higher rates of relapse stage for stage compared to ER/PR positive and HER2 positive breast cancers despite optimal loco-regional and systemic therapies. To date, not a single targeted therapy has been approved for the treatment of TNBC, and cytotoxic chemotherapy remains the standard systemic treatment. Recently, gene expression analyses identified six distinct TNBC subtypes, each displaying a unique biology. In this review we will discuss current and upcoming therapeutic strategies exploring novel approaches to targeted treatment of these TNBC subtypes.

Entities:  

Keywords:  TNBC; Triple negative breast cancer; gene expression profiles; targeted therapy

Year:  2014        PMID： 25419441      PMCID： PMC4235783          DOI： 10.1007/s12609-014-0152-1

Source DB:  PubMed          Journal:  Curr Breast Cancer Rep        ISSN： 1943-4588


  29 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas).

Authors:  Emad A Rakha; Ian O Ellis; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2008-08       Impact factor: 7.842

3.  Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

Authors:  Jorma J de Ronde; Juliane Hannemann; Hans Halfwerk; Lennart Mulder; Marieke E Straver; Marie-Jeanne T F D Vrancken Peeters; Jelle Wesseling; Marc van de Vijver; Lodewyk F A Wessels; Sjoerd Rodenhuis
Journal:  Breast Cancer Res Treat       Date:  2009-08-08       Impact factor: 4.872

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

Authors:  Fabrice Andre; Bastien Job; Philippe Dessen; Attila Tordai; Stefan Michiels; Cornelia Liedtke; Catherine Richon; Kai Yan; Bailang Wang; Gilles Vassal; Suzette Delaloge; Gabriel N Hortobagyi; W Fraser Symmans; Vladimir Lazar; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Authors:  Yasir H Ibrahim; Celina García-García; Violeta Serra; Lei He; Kristine Torres-Lockhart; Aleix Prat; Pilar Anton; Patricia Cozar; Marta Guzmán; Judit Grueso; Olga Rodríguez; Maria Teresa Calvo; Claudia Aura; Orland Díez; Isabel T Rubio; José Pérez; Jordi Rodón; Javier Cortés; Leif W Ellisen; Maurizio Scaltriti; José Baselga
Journal:  Cancer Discov       Date:  2012-08-22       Impact factor: 39.397

8.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

Review 9.  Targeting the DNA repair defect of BRCA tumours.

Authors:  Nicholas Turner; Andrew Tutt; Alan Ashworth
Journal:  Curr Opin Pharmacol       Date:  2005-08       Impact factor: 5.547

10.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.

Authors:  Jorge S Reis-Filho; Kay Savage; Maryou B K Lambros; Michelle James; Dawn Steele; Robin L Jones; Mitch Dowsett
Journal:  Mod Pathol       Date:  2006-04-28       Impact factor: 7.842
View more
  27 in total

1.  Quantitative assessment of breast cancer liver metastasis expansion with patient-derived xenografts.

Authors:  Mohammad A Alzubi; Sahib S Sohal; Madhumitha Sriram; Tia H Turner; Patricija Zot; Michael Idowu; J Chuck Harrell
Journal:  Clin Exp Metastasis       Date:  2019-05-08       Impact factor: 5.150

2.  Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.

Authors:  Elaine M Walsh; Ayca Gucalp; Sujata Patil; Marcia Edelweiss; Dara S Ross; Pedram Razavi; Shanu Modi; Neil M Iyengar; Rachel Sanford; Tiffany Troso-Sandoval; Mila Gorsky; Jacqueline Bromberg; Pamela Drullinsky; Diana Lake; Serena Wong; Patricia Ann DeFusco; Nicholas Lamparella; Ranja Gupta; Tasmila Tabassum; Leigh Ann Boyle; Artavazd Arumov; Tiffany A Traina
Journal:  Breast Cancer Res Treat       Date:  2022-08-20       Impact factor: 4.624

Review 3.  Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC).

Authors:  Aiswarya Chaudhuri; Dulla Naveen Kumar; Deepa Dehari; Sanjay Singh; Pradeep Kumar; Pradeep Kumar Bolla; Dinesh Kumar; Ashish Kumar Agrawal
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

4.  CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification.

Authors:  Jae Young Hur; Hyeong Ryul Kim; Jung Yeon Lee; Sojung Park; Ji An Hwang; Woo Sung Kim; Shinkyo Yoon; Chang-Min Choi; Jin Kyung Rho; Jae Cheol Lee
Journal:  Cell Oncol (Dordr)       Date:  2019-03-05       Impact factor: 6.730

5.  Leptin Signaling Mediates Obesity-Associated CSC Enrichment and EMT in Preclinical TNBC Models.

Authors:  Laura W Bowers; Emily L Rossi; Shannon B McDonell; Steven S Doerstling; Subreen A Khatib; Claire G Lineberger; Jody E Albright; Xiaohu Tang; Linda A deGraffenried; Stephen D Hursting
Journal:  Mol Cancer Res       Date:  2018-02-16       Impact factor: 5.852

6.  Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.

Authors:  Andrew J Robles; Shengxin Cai; Robert H Cichewicz; Susan L Mooberry
Journal:  Breast Cancer Res Treat       Date:  2016-06-02       Impact factor: 4.872

7.  Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells.

Authors:  Andrew J Robles; Shelby McCowen; Shengxin Cai; Michaels Glassman; Francisco Ruiz; Robert H Cichewicz; Stanton F McHardy; Susan L Mooberry
Journal:  J Med Chem       Date:  2017-11-03       Impact factor: 7.446

8.  Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer.

Authors:  Andrew J Robles; Lin Du; Robert H Cichewicz; Susan L Mooberry
Journal:  J Nat Prod       Date:  2016-06-16       Impact factor: 4.050

9.  Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155).

Authors:  Tasaduq Hussain Wani; Goutam Chowdhury; Anindita Chakrabarty
Journal:  RSC Med Chem       Date:  2021-02-15

10.  Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison.

Authors:  Qin He; Yicheng Peng; Jie Sun; Jianxia Liu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.